Valuation: Agios Pharmaceuticals, Inc.

Market Cap 2.54B 2.23B 2.05B 1.9B 3.6B 243B 3.66B 24.53B 9.63B 120B 9.55B 9.35B 411B P/E 2026 *
-6.85x
P/E 2027 * -9.17x
Enterprise Value 2.23B 1.95B 1.8B 1.66B 3.15B 212B 3.2B 21.46B 8.43B 105B 8.36B 8.18B 360B EV / Sales 2026 *
18.5x
EV / Sales 2027 * 9.18x
Free-Float
77.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agios Pharmaceuticals, Inc.

1 day-3.75%
1 week+9.90%
Current month+10.72%
1 month+42.28%
3 months+24.82%
6 months+45.09%
Current year+50.96%
1 week 36.77
Extreme 36.77
44.09
1 month 28.16
Extreme 28.165
44.09
Current year 24.29
Extreme 24.29
44.09
1 year 22.24
Extreme 22.24
46
3 years 19.8
Extreme 19.795
62.58
5 years 16.75
Extreme 16.75
62.58
10 years 16.75
Extreme 16.75
99.82
Manager TitleAgeSince
Chief Executive Officer 57 2022-08-07
Director of Finance/CFO 51 2022-09-25
Chief Tech/Sci/R&D Officer 47 2021-08-31
Director TitleAgeSince
Director/Board Member 66 2014-12-08
Director/Board Member 73 2015-06-22
Director/Board Member 73 2017-05-26
Date Insider Type Main position Quantity % Market Cap.
06-30Fiscal year

Chief Technology Officer

20,757 0.0349%
06-17Fiscal year

Executive/Senior Manager

-6,000 0.0101%
06-17Fiscal year

Chief Financial Officer

-6,000 0.0101%
Change 5-day change 1-year change 3-year change Capi.($)
-3.75%+9.90%+3.95%+53.26% 2.54B
-4.14%-8.06%+57.35%+117.24% 56.98B
+1.84%+1.65%+76.90%+95.68% 53.58B
-3.86%+2.13%+17.86%+458.43% 25.63B
-1.86%-2.76%-19.82%-14.98% 23.51B
+2.43%+5.86%+46.56%+0.42% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+10.46%+47.66% - 14.13B
-1.01%+1.65%+24.96%+195.99% 14.35B
Average -1.21%+2.43%+49.24%+136.37% 24.48B
Weighted average by Cap. -1.27%+0.43%+54.28%+136.17%

Financials

2026 *2027 *
Net sales 120M 105M 97.14M 89.72M 170M 11.48B 173M 1.16B 456M 5.66B 452M 442M 19.45B 262M 230M 212M 196M 371M 25.03B 377M 2.53B 994M 12.33B 985M 964M 42.39B
Net income -371M -324M -299M -276M -524M -35.35B -533M -3.57B -1.4B -17.41B -1.39B -1.36B -59.87B -287M -251M -231M -214M -405M -27.34B -412M -2.76B -1.09B -13.47B -1.08B -1.05B -46.3B
Net Debt -319M -279M -257M -238M -451M -30.4B -458M -3.07B -1.21B -14.98B -1.2B -1.17B -51.48B -136M -119M -110M -102M -193M -13.02B -196M -1.32B -517M -6.41B -512M -501M -22.04B
Logo Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Employees
540
Date Price Change Volume
26-07-10 US$41.09 -3.97% 584,785
26-07-09 US$42.79 +0.07% 520,058
26-07-08 US$42.76 -2.84% 1,618,459
26-07-07 US$44.01 +17.71% 2,776,297
26-07-06 US$37.39 -0.51% 476,106
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
42.79USD
Average target price
42.62USD
Spread / Average Target
-0.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGIO Stock